• Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)
    • Services
      • Equity Reports (Analyst-Ready)
      • Visibility Upgrades (Quartely + As needed)
      • Investor Mapping
    • Press
    • Ask AI
    • Contact
    • English
      • Deutsch (German)
      • 日本語 (Japanese)
  • info@vasro.de
  • +49 (0)69 90 28 39 81
  • Call us Mon - Fri: 8:30 AM - 6:00 PM
VASRO GmbH
VASRO GmbH
  • Services
    • Equity Reports (Analyst-Ready)
    • Visibility Upgrades (Quartely + As needed)
    • Investor Mapping
  • Press
  • Ask AI
  • Contact
  • English
    • Deutsch (German)
    • 日本語 (Japanese)

Press

VASRO GmbH > Press

Why Regulatory Changes Shape the Pharma Market

  • December 12, 2024
  • Pharma & Biotech
Understand the impact of regulatory changes on the pharma market, shaping drug development, pricing, and innovation while ensuring safety and compliance.
Continue Reading

GSK Joins Forces with Muna Therapeutics for Alzheimer’s Breakthroughs

  • December 10, 2024
  • Pharma & Biotech
GSK partners with Muna Therapeutics for Alzheimer's research, leveraging the MiND-MAP platform to uncover novel drug targets and advance treatment breakthroughs.
Continue Reading

How Hedge Funds Use Medical Expertise to Gain Pharma Insights

  • December 9, 2024
  • Pharma & Biotech
Inside the strategy: How hedge funds leverage medical experts for pharma insights, improving decision-making, mitigating risks, and identifying high-value opportunities.
Continue Reading

Explore Our Market Intelligence Pool – Tailored Insights for Your Needs

  • December 6, 2024
  • Market Intelligence, Market Intelligence
At VASRO GmbH, we’ve built an extensive pool of Market Intelligence Reports, covering key trends, sector analyses, and emerging opportunities. While we continue to produce timely and high-quality reports,...
Continue Reading

Eli Lilly Gains Ground Against Novo Nordisk in Weight-Loss Drugs

  • December 6, 2024
  • Pharma & Biotech
The battle of the weight-loss behemoths: Eli Lilly whomps Novo Nordisk as Zepbound outpaces Wegovy in efficacy, reshaping the obesity drug market.
Continue Reading

Q3 2024 Performance Analysis: Top 10 EU Bond Funds

  • December 5, 2024
  • Market Intelligence
This report analyzes the performance of the ten largest bond funds in the European Union during the third quarter (Q3) of 2024, offering insights into the dynamics of the...
Continue Reading

Why private equity is fueling growth in the tech sector

  • December 5, 2024
  • Tech
Private equity drives tech sector growth by leveraging scalability, recurring revenue models, and innovation, as shown in Tech Sector Investment Analysis.
Continue Reading

How Market Intelligence Supports Proactive Decision Making

  • December 4, 2024
  • Pharma & Biotech, Tech
Market intelligence for decision making helps businesses analyze data, predict trends, and make proactive, strategic decisions to stay competitive and reduce risks.
Continue Reading

How AI is Enhancing Decision-Making in Tech Equity Research

  • December 3, 2024
  • Tech
AI is transforming equity research in tech by enhancing decision-making, improving efficiency, and delivering actionable insights for the fast-paced technology sector.
Continue Reading

2024 Technology Breakthroughs That Will Define the Year

  • December 2, 2024
  • Tech
Explore the Top Tech Trends for 2024, from AI and quantum computing to renewable energy and XR, reshaping industries and enhancing daily life.
Continue Reading

Posts pagination

Previous 1 … 30 31 32 … 37 Next

Search

Categories

  • Energy
  • Equity Analysis reports
  • Equity Research Coverage
  • Market Intelligence
  • Pharma & Biotech
  • Tech
  • Unkategorisiert

Recent Posts

Sirnaomics Ltd.: The RNAimmune Money Is In, and the FDA Has Answered in Writing on STP705 October 12, 2026
Ainos, Inc.: A Partner Pays for VELDONA, and Ainos Keeps the Platform September 29, 2026
Ainos Inc: A Front-End Customer Starts Ordering, and the Dataset Passes a Billion September 16, 2026
Ainos, Inc.: Three Patents Approved in Japan, and a Dataset Gathering Pace September 11, 2026
Baladna: The Capital Is Raised, Algeria Is Building – VASRO Reiterates BUY at QAR 2.33 September 7, 2026
VASRO GmbH
VASRO GmbH specializes in equity analysis, market intelligence, and investment strategy for the pharmaceutical, biotechnology, and IT sectors. We deliver tailored insights to drive informed investment decisions and achieve exceptional results.

Discover More

Contact Info

  • Am Hauptbahnhof 16, 60329 Frankfurt am Main, Germany
  • +49 (0)69 90 28 39 81
  • info@vasro.de
  • 8:30 AM - 6:00 PM

Navigation

  • Imprint
  • Privacy Policy
  • Change privacy settings
  • Application
  • About
  • FAQ

©copyright 2025 VASRO GmbH.